Fentanyl (transmucosal)

Journal of Pain and Symptom Management

Volumn 44, Issue 1, 2012, Pages 131-149

  Twycross, Robert ^a   Prommer, Eric E ^b   Mihalyo, Mary ^c   Wilcock, Andrew ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MAYO CLINIC   (United States)

^c DUQUESNE UNIVERSITY   (United States)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; CARBAMAZEPINE; CIMETIDINE; CLARITHROMYCIN; DILTIAZEM; ERYTHROMYCIN; FENTANYL; FENTANYL CITRATE; FLUCONAZOLE; HYDROMORPHONE; ITRACONAZOLE; KETOCONAZOLE; MORPHINE; NELFINAVIR; OXYCODONE; PHENOBARBITAL; PHENYTOIN; PLACEBO; RIFAMPICIN; RITONAVIR; VERAPAMIL;

CONFUSION; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; EPISTAXIS; HUMAN; MOUTH DISCOMFORT; MUCOSAL ADMINISTRATION; NAUSEA AND VOMITING; PATIENT SELECTION; REVIEW; RHINORRHEA; SINGLE DRUG DOSE; SORE THROAT; ULCER;

EID: 84863583169     PISSN: 08853924     EISSN: 18736513     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2012.05.001     Document Type: Short Survey

References (70)

1. X. Gomez-Batiste, F. Madrid, and F. Moreno Breakthrough cancer pain: prevalence and characteristics in Catalonia J Pain Symptom Manage 24 2002 45 52
2. G. Zeppetella Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief J Pain Symptom Manage 35 2008 563 567
3. M. Darwish, M. Kirby, P. Robertson Jr., W. Tracewell, and J.G. Jiang Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate J Clin Pharmacol 47 2007 343 350
4. European Medicines Agency. Assessment report for Pecfent. 2010. Procedure No. EMA/H/C/001164.
5. European Medicines Agency. Effentora: EPAR - Scientific discussion. 2008.
6. N. Vasisht, L.N. Gever, I. Tagarro, and A.L. Finn Single-dose pharmacokinetics of fentanyl buccal soluble film Pain Med 11 2010 1017 1023
7. A.L. Finn, N. Vasisht, J.G. Stark, L.N. Gever, and I. Tagarro Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study Clin Drug Investig 32 2012 63 71
8. J.L. Lichtor, F.B. Sevarino, and G.P. Joshi (1999) The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain Anesth Analg 89 1999 732 738
9. M. Darwish, M. Kirby, P. Robertson, W. Tracewell, and J.G. Jiang Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study Clin Drug Investig 27 2007 605 611
10. A.L. Finn, W.C. Hill, I. Tagarro, and L.N. Gever Absorption and tolerability of fentanyl buccal soluble film (FBSF) in patients with cancer in the presence of oral mucositis J Pain Res 4 2011 245 251
11. U.S. Food and Drug Administration Center for drug evaluation and research Summary review 2009 Application number 22-266
12. M. Darwish, M. Kirby, P. Robertson Jr., E. Hellriegel, and J.G. Jiang Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics Clinical Pharmacokinet 45 2006 843 850
13. S. Kaasa, K. Moksnes, and T. Nolte Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain Journal of Opioid Manag 6 2010 17 26
14. European Medicines Agency. Assessment report for Instanyl. 2009. Procedure No. EMEA/H/C/959. London.
15. M. Darwish, M. Kirby, P. Robertson Jr., W. Tracewell, and J.G. Jiang Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microgram in healthy adult volunteers Clin Ther 28 2006 707 714
16. N. Vasisht, L.N. Gever, I. Tagarro, and A.L. Finn Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers J Clin Pharmacol 50 2010 785 791
17. M. Darwish, M. Kirby, P. Robertson Jr., E. Hellriegel, and J.G. Jiang Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers J Clin Pharmacol 47 2007 56 63
18. R.L. Rauck, M. Tark, and E. Reyes Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain Curr Med Res Opin 25 2009 2877 2885
19. N.E. Slatkin, F. Xie, J. Messina, and T.J. Segal Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain J Support Oncol 5 2007 327 334
20. R.K. Portenoy, A.W. Burton, and N. Gabrail A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain Pain 151 2010 617 624
21. R.K. Portenoy, W. Raffaeli, and L.M. Torres Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients J Opioid Manag 6 2010 319 328
22. R. Rauck, J. North, L.N. Gever, I. Tagarro, and A.L. Finn Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study Ann Oncol 21 2010 1308 1314
23. European Medicines Agency. Committee for medicinal products for human use (CHMP). 2008. Opinion following article 29(4) referral for Rapinyl.
24. R.H. Dworkin, D.C. Turk, and K.W. Wyrwich Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations J Pain 9 2008 105 121
25. H.G. Kress, A. Orońska, and Z. Kaczmarek Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period Clin Ther 31 2009 1177 1191
26. Prostraken. Personal communication, 2010.
27. P.H. Coluzzi, L. Schwartzberg, and J.D. Conroy Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR) Pain 91 2001 123 130
28. G. Zeppetella, J. Messina, F. Xie, and N.E. Slatkin Consistent and clinically relevant effects with fentanyl buccal tablet in the treatment of patients receiving maintenance opioid therapy and experiencing cancer-related breakthrough pain Pain Pract 10 2010 287 293
29. M.A. Ashburn, K.A. Slevin, J. Messina, and F. Xie The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain Anesth Analg 112 2011 693 702
30. M. Fallon, C. Reale, A. Davies Fentanyl Nasal Spray Study 044 Investigators Group Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study J Support Oncol 9 2011 224 231
31. A. Davies, T. Sitte, and F. Elsner Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain J Pain Symptom Manage 41 2011 358 366
32. S. Mercadante, L. Radbruch, and A. Davies A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open label, randomised, crossover trial Curr Med Res Opin 25 2009 2805 2815
33. J. Säwe, B. Dahlström, and A. Rane Steady-state kinetics and analgesic effect of oral morphine in cancer patients Eur J Clin Pharmacol 24 1983 537 542
34. E. Freye, J.V. Levy, and D. Braun Effervescent morphine results in faster relief of breakthrough pain in patients compared to immediate release morphine sulfate tablet Pain Pract 7 2007 324 331
35. R. England, M. Maddocks, C. Manderson, S. Zadora-Chrzastowska, and A. Wilcock How practical are transmuscosal fentanyl products for breakthrough cancer pain? Novel use of placebo formulations to survey user opinion BMJ Support Palliat Care 1 2011 349 351
36. J. Gardner-Nix Oral transmucosal fentanyl and sufentanil for incident pain J Pain Symptom Manage 22 2001 627 630
37. G. Zeppetella Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study Palliat Med 15 2001 323 328
38. Palliativedrugs.com. Hot Topics: alternatives to sublingual fentanyl. In: August 2003 Newsletter. Available from www.palliativedrugs.com.
39. A. Duncan The use of fentanyl and alfentanil sprays for episodic pain Palliat Med 16 2002 550
40. M. Finn, and D. Harris Intranasal fentanyl for analgesia in the paediatric emergency department Emerg Med J 27 2010 300 301
41. J. Cole, M. Shepherd, and P. Young Intranasal fentanyl in 1-3-year-olds: a prospective study of the effectiveness of intranasal fentanyl as acute analgesia Emerg Med Australas 21 2009 395 400
42. S. Mudd Intranasal fentanyl for pain management in children: a systematic review of the literature J Pediatr Health Care 25 2011 316 322
43. M. Borland, S. Milsom, and A. Esson Equivalency of two concentrations of fentanyl administered by the intranasal route for acute analgesia in children in a paediatric emergency department: a randomized controlled trial Emerg Med Australas 23 2011 202 208
44. K. Baxter (2010) Stockley's drug Interactions (online edition) 2010 The Pharmaceutical Press London Available from www.medicinescomplete.com
45. E.D. Kharasch, D. Whittington, and C. Hoffer Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate Anesthesiology 101 2004 729 737
46. H. Takane, A. Nosaka, H. Wakushima, K. Hosokawa, and I. Ieiri Rifampin reduces the analgesic effect of transdermal fentanyl Ann Pharmacother 39 2005 2139 2140
47. M. Sasson, and P. Shvartzman Fentanyl patch sufficient analgesia for only one day J Pain Symptom Manage 31 2006 389 391
48. H. Morii, M. Chiba, H. Konishi, Y. Endo, and A. Yamaji Failure of pain control using transdermal fentanyl during rifampicin treatment J Pain Symptom Manage 33 2007 5 6
49. Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) program. 2012. Available from http://www. tirfremsaccess.com.
50. P.G. Fine, J. Messina, F. Xie, and J. Rathmell Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study J Pain Symptom Manage 40 2010 747 760
51. J.D. Markman Not so fast: the reformulation of fentanyl and breakthrough chronic non-cancer pain Pain 136 2008 227 229
52. S.D. Passik, J. Messina, A. Golsorkhi, and F. Xie Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain J Pain Symptom Manage 41 2010 116 125
53. J.M. Nunez-Olarte, and P. Alvarez-Jimenez Emerging opioid abuse in terminal cancer patients taking oral transmucosal fentanyl citrate for breakthrough pain J Pain Symptom Manage 42 2011 e6 e8
54. J.M. Christie, M. Simmonds, and R. Patt Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain J Clin Oncol 16 1998 3238 3248
55. R.K. Portenoy, R. Payne, and P. Coluzzi Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled use titration study Pain 79 1999 303 312
56. R.K. Portenoy, D. Taylor, J. Messina, and L. Tremmel A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer Clin J Pain 22 2006 805 811
57. S.R. Nalamachu, R.L. Rauck, M.S. Wallace, D. Hassman, and J. Howell (2012) Successful dose finding with sublingual fentanyl tablet: combined results from 2 open-label titration studies Pain Pract 2012 Jan 9 10.1111/j.1533-2500. 2011.00525.x [Epub ahead of print]
58. S. Nalamachu, D. Hassman, and M.S. Wallace Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain Curr Med Res Opin 27 2011 519 530
59. A.N. Davies, and J. Vriens Oral transmucosal fentanyl citrate and xerostomia J Pain Symptom Manage 30 2005 496 497
60. R. Payne, P. Coluzzi, and L. Hart Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain J Pain Symptom Manage 22 2001 575 583
61. G.W. Hanks, M. Nugent, and C.M. Higgs Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study Palliat Med 18 2004 698 704
62. M. Darwish, M. Kirby, J.G. Jiang, W. Tracewell, and P. Robertson Jr. Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects Clin Drug Investig 28 2008 1 7
63. S.M. Weinstein, J. Messina, and F. Xie Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: a long-term, open-label safety study Cancer 115 2009 2571 2579
64. S. Mercadante, P. Ferrera, C. Adile, and A. Casuccio Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose J Pain Symptom Manage 42 2011 464 469
65. D.M. Simpson, J. Messina, F. Xie, and M. Hale Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study Clin Ther 29 2007 588 601
66. R.K. Portenoy, J. Messina, F. Xie, and J. Peppin Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study Curr Med Res Opin 23 2007 223 233
67. J.T. Farrar, J. Messina, F. Xie, and R.K. Portenoy A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain Pain Med 11 2010 1313 1327
68. M.L. Shear, J.N. Adler, and S. Shewakramani (2010) Transbuccal fentanyl for rapid relief of orthopedic pain in the ED Am J Emerg Med 28 2010 847 852
69. Meda Pharmaceuticals Ltd. Personal communication, 2012.
70. Insys Pharma. Personal communication, 2012.